Generic Name:
lanadelumab
Project Status:
Complete
Therapeutic Area:
Hereditary angioedema, prevention
Manufacturer:
Shire Pharma Canada ULC
Call for patient/clinician input open:
Brand Name:
Takhzyro
Project Line:
Reimbursement Review
Project Number:
SR0618-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For routine prevention of attacks of hereditary angioedema (HAE) in adolescents and adults.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Hereditary angioedema, prevention
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.